Otero Jose Manuel 4
4 · Lexeo Therapeutics, Inc. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Lexeo (LXEO) COO Jose Manuel Otero Receives RSU Award
What Happened
Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics (LXEO), received equity awards on February 4, 2026 totaling 325,000 restricted stock units (RSUs): 65,000 RSUs listed as an acquisition and 260,000 RSUs reported as a derivative award. Both awards were granted at a reported purchase price of $0.00 (no cash exchanged at grant).
Key Details
- Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely filing).
- Grants: 65,000 RSUs (acquisition) and 260,000 RSUs (derivative); both $0.00 per share (total reported value $0).
- Vesting for these RSUs (per filing footnote F1): 25% vest on Feb 15, 2027, then 1/16th of the RSUs vest on the company’s standard quarterly vesting dates thereafter, subject to continued service.
- Footnote F2: filing notes “Includes 112,733 RSUs” (these are included in the reported holdings/amounts).
- Footnote F3: separately describes an option vesting schedule (25% on Feb 4, 2027, then 1/48th monthly) likely related to previously granted options.
- No immediate sale of shares or cashless exercise reported; these are time/service‑based awards, not open‑market purchases or sales.
Context
This is an equity grant (award) rather than an open‑market purchase or sale. Grants are common as compensation and vest over time contingent on continued service; they do not by themselves indicate an immediate vote of confidence via a market purchase. The derivative designation simply reflects these are RSUs (a contingent right to receive shares upon vesting).
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-04+65,000→ 128,476 total - Award
Stock Option (right to buy)
[F3]2026-02-04+260,000→ 260,000 totalExercise: $7.27Exp: 2036-02-03→ Common Stock (260,000 underlying)
Footnotes (3)
- [F1]The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Includes 112,733 RSUs.
- [F3]25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.